Sarepta Therapeutics stock is trading -26.06% below its average target price of $167.9 after marking a 5.7% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $128.0 to $224.0 per share.
Sarepta Therapeutics has an average level of shares sold short, at 7.3% of its total share float. The stock's short ratio (also called days to cover) is 6.08. The company's insiders own 4.41% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 88.6% of Sarepta Therapeutics's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Sarepta Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 9% | 8,795,754 | $1,091,992,872 |
| 2024-03-31 | Blackrock Inc. | 6% | 5,960,370 | $739,979,944 |
| 2024-03-31 | Janus Henderson Group PLC | 5% | 4,891,417 | $607,269,428 |
| 2024-03-31 | Capital International Investors | 5% | 4,817,517 | $598,094,742 |
| 2024-03-31 | Avoro Capital Advisors LLC | 5% | 4,344,444 | $539,362,729 |
| 2024-03-31 | Wellington Management Group, LLP | 3% | 3,245,798 | $402,965,826 |
| 2024-03-31 | Farallon Capital Management LLC | 3% | 2,453,500 | $304,602,028 |
| 2024-03-31 | State Street Corporation | 2% | 2,122,491 | $263,507,260 |
| 2024-03-31 | Bank Of New York Mellon Corporation | 2% | 2,067,037 | $256,622,646 |
| 2024-03-31 | T. Rowe Price Investment Management, Inc. | 2% | 1,931,547 | $239,801,562 |
